Skip to main content

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed · Phase 3 · NCT05463744

Conditions: Type 1 Diabetes, Diabetes

At a glance

Research payments reported, 2025
$67,660
U.S. investigators named
8
Sites paid
8
Planned or actual enrollment
692

About the trial

Sponsor
Eli Lilly and Company
Tested
Insulin Efsitora Alfa (drug), Insulin Degludec (drug)
Dates
Started 2022-08-12; completion 2024-05-07
Results posted
Yes

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.

From ClinicalTrials.gov, last updated 2025-06-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $67,660 in research payments for this study in 2025 (8 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Rocky Mountain Clinical Research LLC $28,445
  • Clinvest Research LLC $7,544
  • David Fitzpatrick MD DBA E West Med Rsrch $7,006
  • New York University $6,995
  • Rainier Clinical Research Center $6,750
  • East Coast Institute for Research $5,020
  • Medstar Health Research Institute $3,150
  • John Muir Med Fndtn DBA John Muir Phys Network $2,750

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.